Preferred Label : Filgotinib Maleate;
NCIt definition : The maleate form of filgotinib, an orally bioavailable inhibitor of the tyrosine kinase
Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities.
Upon oral administration, filgotinib specifically targets, binds to, and inhibits
the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and
activator of transcription)-dependent signaling. As JAK1 mediates signaling of many
pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity
in many inflammatory and immune-mediated processes and leads to a decrease in inflammation
and activation of certain immune cells. JAK1 plays a key role in the signaling and
activity of many cytokines and growth factors and is often dysregulated in a variety
of autoimmune and inflammatory diseases, as well as some malignancies.;
UNII : JG8OB4UL9Y;
InChIKey : BFENHEAPFWQJFL-BTJKTKAUSA-N;
CAS number : 1802998-75-9;
NCI Metathesaurus CUI : CL1405881;
Origin ID : C171929;
UMLS CUI : C5419370;
Semantic type(s)
- concept_is_in_subset
https://www.has-sante.fr/jcms/p_3343855/fr/jyseleca-filgotinib-rectocolite-hemorragique
2022
false
false
false
France
filgotinib
filgotinib
Filgotinib Maleate
adult
female
treatment outcome
insurance, health, reimbursement
administration, oral
evaluation of the transparency committee
colitis, ulcerative
---
